A5006324385- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- T-cell and Retrovirus Studies
- Sarcoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Cancer-related cognitive impairment studies
- Brain Metastases and Treatment
- Gastrointestinal Tumor Research and Treatment
- Neutropenia and Cancer Infections
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Chronic Myeloid Leukemia Treatments
- Cutaneous lymphoproliferative disorders research
Austin Health
2016-2025
Olivia Newton-John Cancer Wellness & Research Centre
2016-2025
Monash University
2016-2025
Austin Hospital
2016-2025
Clinical Innovations (United States)
2025
Eastern Health
2015-2024
The University of Melbourne
2018-2024
La Trobe University
2018-2024
Monash Health
2017-2024
Melbourne Health
2023
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal (EGFR) inhibition and may represent a therapeutic target. We conducted multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer. Eligible patients were randomly assigned dalotuzumab 10mg/kg weekly (arm A), 7.5mg/kg every alternate week B), or placebo C) combination...
BackgroundCentral nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis CNS for patients treated within the UK NCRI phase III R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) 14 versus 21 randomised trial.Patients methodsThe trial compared administered two- three weekly in previously untreated aged ≥18 years bulky stage I–IV DLBCL (n = 1080). Details prophylaxis were...
Outcomes with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) or CHOP-like chemotherapy in peripheral T-cell lymphoma are poor. We investigated whether the regimen of gemcitabine, cisplatin, methylprednisolone (GEM-P) was superior to as front-line therapy previously untreated patients.We did a phase 2, parallel-group, multicentre, open-label randomised trial 47 hospitals: 46 UK one Australia. Participants were patients aged 18 years older bulky (tumour mass diameter >10...
Abstract Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of phosphatidylinositol 3-kinase inhibitor copanlisib in patients DLBCL assessed relationship between cell origin (COO; activated like [ABC] germinal center [GCB]) other biomarkers. The primary endpoint was objective response rate (ORR) COO subgroups (ABC, GCB, unclassifiable) by CD79B mutational status (NCT02391116). Sixty-seven received (ABC DLBCL, n...
Abstract Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary acquired molecular determinants of response resistance marginal zone lymphoma (MZL) zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline samples obtained from 18 patients. For 7 patients, ctDNA sequence interrogated using a bespoke hybrid-capture...
The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL), favorable safety/tolerability profile. Presented here, is final performed to characterize durability and longer-term safety tolerability. Zanubrutinib (160 mg twice daily) was evaluated 68 R/R MZL who...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent targeted agents. Real-world analysis patients CLL provides a better understanding treatment efficacy and toxicity informs planning future trials; however, Australasian studies are limited. Here we describe demographics, disease characteristics, outcome for enrolled in Australia New Zealand Lymphoma Related Diseases Registry (LaRDR). This study included 365 aged ≥18 years diagnosed between January 2016...
Summary Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL ibrutinib. We analysed 33 patients who received ibrutinib, alone or other therapies, for PCNSL ( n = 9) SCNSL 24). The objective response rate was 58% (complete 55%). median progression‐free survival overall were both 3·1 months; SCNSL, 10·2 11·5 months...
The International Prognostic Score (IPS) has been used in classic Hodgkin lymphoma (cHL) for 25 years. However, analyses have documented suboptimal performance of the IPS among contemporarily treated patients. Harnessing multisource individual patient data from Lymphoma Study Individual Care consortium, we developed and validated a modern clinical prediction model.
Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high FL patients harmonize clinical trial populations. The utilization of GELF (GELFc) in routine therapeutic decision- making poorly described. This multicenter retrospective study evaluated patterns GELFc at presentation decision-making newly diagnosed, advanced-stage...
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use definitions trial designs varies significantly it is unclear how this influenced the relevance of bulk contemporary practice. This comprehensive literature review evaluated definitions, applications impact phase 3 randomised trials four major lymphoma subtypes. Overall, 87 studies were identified across follicular (FL), diffuse large...
Not available.